Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 13

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 13
---
 will also likely be subject to the regulations and restrictions regarding trading in “penny stocks,” which are those securities trading for less than $5.00 per share, and that are not otherwise exempted from the definition of a penny stock under other exemptions provided for in the applicable regulations. These penny stock requirements and regulations could severely limit the liquidity of our common stock in the secondary market because fewer brokers or dealers would be likely to be willing to undertake related compliance activities to trade in our common stock. If our common stock is not listed on a national securities exchange, the rules and restrictions regarding penny stock transactions may limit an investor’s ability to sell to a third-party and our trading activity in the secondary market may be reduced. Delisting from The Nasdaq Capital Market would also likely limit the range and attractiveness of strategic alternatives that we are able to consider, adversely affect our ability to raise additional capital through the public or private sale of equity securities, significantly affect the ability of investors to trade our securities, and/or negatively affect the value and liquidity of our common stock. The Common Stock Warrants are not exercisable until Stockholder Approval and may not have any value. Under Nasdaq listing rules, the Common Stock Warrants are not exercisable without Stockholder Approval for the issuance of shares issuable upon exercise of such Common Stock Warrants. While we intend to use reasonable best efforts to seek Stockholder Approval for issuances of shares of common stock issuable upon exercise of the Common Stock Warrants, there is no guarantee that the Stockholder Approval will ever be obtained. The Common Stock Warrants will be exercisable commencing on the date Stockholder Approval is obtained, at an initial exercise price per share of $ per share. In the event that the price of a share of our common stock does not exceed the exercise price of the Common Stock Warrants during the period when the Common Stock Warrants are exercisable, the Common Stock Warrants may not have any value. If we are unable to obtain the Stockholder Approval, the Common Stock Warrants will not be exercisable and therefore would have no value. In addition, we may incur substantial cost, and management may devote substantial time and attention, in attempting to obtain Stockholder Approval of the issuance of shares of common stock upon exercise of the Common Stock Warrants issued in this offering. 9 Holders of the warrants offered hereby will have no rights as common stockholders with respect to the shares our common stock underlying the warrants until such holders exercise their warrants and acquire our common stock, except as otherwise provided